Results 311 to 320 of about 221,113 (351)

Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas

Nature Biotechnology, 2020
Reuben Moncada, Dalia Barkley, Florian Wagner   +2 more
exaly  

Learning to distinguish progressive and non-progressive ductal carcinoma in situ

Nature Reviews Cancer, 2022
Mathilde Matthea Machteld Almekinders, Charlotta Mulder, Deborah Collyar   +2 more
exaly  

The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities

Nature Reviews Clinical Oncology, 2020
Won Jin Ho, Elizabeth M Jaffee, Lei Zheng   +2 more
exaly  

Translational advances in pancreatic ductal adenocarcinoma therapy

Nature Cancer, 2022
Abdel Hosein, Stephanie K Dougan, Andrew J Aguirre   +2 more
exaly  

[Ductal carcinoma].

Zhonghua wai ke za zhi [Chinese journal of surgery], 1998
J P, CHU, L Y, SHEU, C Y, CHONG, Y Y, LEE   +3 more
openaire   +1 more source

Ductal Carcinoma in situ

European Journal of Cancer, 1993
openaire   +1 more source

Standard for the Management of Ductal Carcinoma In Situ of the Breast (DCIS)

Ca-A Cancer Journal for Clinicians, 2002
Monica Morrow
exaly  

Challenges in ductal carcinoma in situ risk communication and decision‐making

Ca-A Cancer Journal for Clinicians, 2012
Ann H Partridge
exaly  

PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC

Signal Transduction and Targeted Therapy, 2020
Xunbin Wei, Shengyu Yang, Jihui Hao
exaly  

Ductal Carcinomas

2011
openaire   +1 more source